Articles On Imugene (ASX:IMU)

Imugene (ASX: IMU) has received firm commitments for a $37.5 million capital raising to advance the development of off-the-shelf (allogeneic) CAR-T drug azer-cel for patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL). T...

Lumos Diagnostics says its US distribution deal is worth up to $487 million Impedimed’s US device sales are on a roll Noxopharm treats its first lupus trial patient   In one of the “largest distribution deals of its type” by an ASX-listed...

The ASX has headed into a downturn this Wednesday, mostly thanks to U.S. CPI data from June suggesting Trump’s tariffs are finally having an impact on inflation, but that hasn’t stopped several companies flying on the forums. Listen to t...

In afternoon trade, the S&P/ASX 200 Index (ASX: XJO) is on course to record a large decline. At the time of writing, the benchmark index is down 0.9% to 8,555.5 points. Four ASX shares that are falling more than most today are listed be...

ASX walks tightrope to slide just 9.7 points All Ords gold sub-index climbs 1.87pc Iron ore prices boost big cap mining stocks ASX slides on renewed tariff threats The ASX 200 finished the day down 0.11%, having plunged a good 20 points i...

This article is part of the daily news updates from FNArena.com. Stay informed with the latest financial, business, and economic insights. Written by Admin Since the February update, an additional 5 patients have been dosed, resulting in 2...

Imugene (ASX:IMU) has been the talk of the HotCopper forums today, with the much-followed immune-oncology researcher seeing two more complete responses (and three partial responses) in its azer-cel CAR T phase 1b trials. Listen to the Ho...

Imugene reports two more ‘complete responders’ in its cell therapy trial Clever Culture Systems shares surge 17% on deal with Big Pharma Novo Nordisk  Compumedics shares vault 24% after full-year update   Imugene (ASX:IMU) will forge ahea...

Highlights: ASX 200 futures down amid global trade tensions and market volatility Donald Trump's tariff escalation targets Canada, EU, and Mexico Silver surges to highest level since 2011; Bitcoin hits new record The ASX 200 is po...

This article is part of the daily news updates from FNArena.com. Stay informed with the latest financial, business, and economic insights. Written by Admin Entering second quarter earnings season in earnest this week for the US will shine a...

ASX biotechs target global cell therapy market, projected to reach ~US$48bn by 2034 Arovella the only ASX-listed biotech delving into CAR iNKT therapies and one of few globally Chimeric aims to ‘break new ground’ in treatment of solid tumo...

The ASX 200 Health Care Index fell 1.05% in June and remains the worst performing sector YTD down 6.64% Morgans healthcare analyst Iain Wilkie said June likely saw some tax loss selling before EOFY  Amplia up 300% in June after complete re...

Highlights ASX200 set for softer open amid rising geopolitical tensions  Uranium segment surges despite financials weighing down  Small caps show strength with notable updates across biotech, rare earths, and energy   The Australi...

Highlights ASX-listed companies increasingly pursue secondary trading access through OTC Markets OTC Markets offers a structure supporting US-dollar trading for international equities ASX entities aim to gain US exposure whi...

The S&P/ASX 200 Health Care Index rose 1.59% in May but remains worst performing sector YTD down 5.65% Morgans healthcare analyst Iain Wilkie said US President Donald Trump’s trade and health policies continue to impact sector Lumos up...

Australia’s S&P/ASX 200 rallied 4.20% in May along with global markets as US-tariff tensions eased All of 11 sectors gained in May, led by tech up almost 20% followed by energy and communication services  Dateline Resources surged 978%...

Highlights  ASX200 futures hint at a positive open  Nasdaq posts strongest monthly rally since 2023  Key economic data in focus this week  The Australian share market is poised for a mild uptick at the start of the week, with S&am...

Highlights ASX 200 sees pressure as financial year-end prompts tax-related equity moves Underperforming stocks including Lake Resources (ASX:LKE) and Core Lithium (ASX:CXO) decline further Selling activity intensifies in seg...

This article is part of the daily news updates from FNArena.com. Stay informed with the latest financial, business, and economic insights. Written by Admin US markets fell last week with tariff tremors re-emerging on Friday with President T...

Good Afternoon and welcome to HotCopper Highlights wrapping up Week 21 of the year, I’m Jon Davidson. In this segment we look at what you’ve been watching and discussing most this week, let’s get into it.  Starting with the most viewed, ...

Anatara has taken a different tack post-trial results, while Chimeric is raising funds and Imugene proposes a share consolidation Heramed falls victim to US healthcare funding cuts D-Day looms for Mayne Pharma holders – or will there be a...

Arovella is one of only a handful of biotechs pursuing CAR-iNKT immunotherapies – and is the only ASX-listed exemplar The “soldiers of the blood stream”, CAR-iNKT cells offer potential advantages including easier off-the-shelf therapies Th...

The US health sector shows signs of stabilising as chaos subsides Immutep will meet with the FDA following “excellent” follow-on trial results When it comes to its sagging share price, Immuron leaves blame-shifting to the defeated Liberals...

The S&P/ASX 200 Health Care Index rose 2.16% in April with the S&P/ASX 200 rallying 3.6% Morgans healthcare analyst Iain Wilkie said April was a marked improvement on recent months Several approvals during April, including for EBR...

Highlights: Dateline Resources’ share price surged after political attention on rare earth minerals. Peninsula Energy experiences leadership changes amid halted trading and a downgrade. Biotech companies Telix and Dimerix fa...

As it clocks one year returns down -72%, Imugene Ltd (ASX:IMU) this week issued a letter to shareholders confirming shareholders’ worst fears – yes, the company is a high cash burn business. That isn’t this finance journalist – once-des...

DroneShield Ltd (ASX: DRO) shares had a sensational start to the week on Monday. The counterdrone technology company's shares jumped 16% to $1.03. Why did DroneShield shares rocket? Investors were scrambling to buy the company's shares foll...

The DroneShield Ltd (ASX: DRO) share price is flying high today. Shares in the S&P/ASX 300 Index (ASX: XKO) drone defence company closed Friday trading for 89 cents. In morning trade on Monday, shares are swapping hands for $1.00 apiece...

Donald Trump exempts “pharmaceuticals” from his tariff blitz ASX device makers mull their US manufacturing plans as Ansell shares plunge Race and Imugene progress their early-stage oncology trials   Liberation Day has spared the pharmaceu...

The DroneShield Ltd (ASX: DRO) share price had a month of ups and downs in March. But the good news for the counter drone technology company's shareholders is that there were more ups than downs. As a result, the company's shares defied the...

The New Hope Corporation Ltd (ASX: NHC) share price is sinking deep into the red on Monday. In morning trade, the coal miner's shares are down 6% to $3.86. Why is the New Hope share price sinking? The good news for shareholders is that tod...

Highlights: ASX market fluctuations bring varied performances across sectors. Health Care and Telecommunications display resilience, while Utilities and Real Estate show a different trajectory. Several ASX-listed companies p...

Highlights: Nanosonics sees market movement following regulatory approval in the United States. Arafura establishes a long-term supply agreement in the rare earth sector. Jatcorp faces market challenges amid international tr...

Good afternoon and welcome to HotCopper’s Market Close for Thursday, I’m Jonathon Davidson. It was another better-looking day for the bourse as the XJO closed above 7,900 points. Looking at sectors, IT took the lead up 2.4% while Mate...

Passive income investors received some welcome news on Tuesday in the form of a big lift in the New Hope Corp Ltd (ASX: NHC) dividend. Shares in the S&P/ASX 200 Index (ASX: XJO) coal stock closed up 8.9% on 18 March, the day the company...

It was a return to red ink for the S&P/ASX 200 Index (ASX: XJO) this Wednesday, as investors lost the steam that had been powering a recovery over the past few trading days. By the time trading w...

Chances are, most ASX investors who buy and sell shares on our markets have never heard of the gold-silver ratio. But if you're a precious metals investor or enthusiast, you've probably heard of this metric. Its use in our modern world is q...

The S&P/ASX 200 Index (ASX: XJO) is having a subdued session on Wednesday. In afternoon trade, the benchmark index is down 0.2% to 7,844 points. Four ASX shares that are not letting that hold them back are listed below. Here's why the...

Highlights: The financial sector leads market gains, while utilities register the biggest decline. Opthea enters voluntary suspension ahead of COAST trial results release. Imugene secures FDA Fast Track Designation for its C...

The selling action dragging the All Ordinaries Index (ASX: XAO) into the red today isn't holding back this surging ASX share. The soaring stock in question is Clover Corp Ltd (ASX: CLV). Shares in the nutritional ingredients company closed...

The ASX has been trading flat at around 7,864 points. Financials has been the best performing sector, up 0.3%, followed by Materials, up 0.15% and Energy, up 0.1%. Utilities has been the worst performer, down 1.1%, followed by Industr...

Emvision to launch remote stroke detection trial It’s a tricky market but biotechs are raising funds Imugene wins FDA fast-track status for cancer program   Ahead of a wider trial, Emvision Medical Devices (ASX:EMV) has taken to the air w...

Imugene Ltd (ASX: IMU) shares are on the move on Wednesday and avoiding the market weakness after the clinical-stage immuno-oncology company announced a major regulatory milestone in the United States. At the time of writing, the ASX stock...

Profit-making ASX biotechs have been caught up in the market rout During Brain Health Week, let’s not forget about dementia risks Argent looks for Malta site deal While few stocks or sectors have escaped the market correction – or almost...

Johns Lyng Group (ASX:JLG) has seen a sharp shares selloff through Monday trade after it was confirmed the insurance repairer would be removed from the ASX 200 when the index reshuffles a little later this month. Listen to the HotCopper...

The S&P/ASX 200 Health Care Index fell 7.66% in February with the S&P/ASX 200 down 3.79% Morgans healthcare analyst Iain Wilkie said several factors caused investor jitters in February including job cuts to US FDA  Pacific Edge was...

Healthcare analysts say Neuren shares should be worth more than double what they are Biotech sector retreats in February, despite some record results Dimerix pockets $3.2 million payment from Japanese partner   Some healthcare analysts be...

Imugene is carrying out three immune-oncology clinical programs that could revolutionise cancer treatment The company could be the first to win approval for an allogeneic (off-the-shelf) CAR-T-based solid cancer drug After a minimum $20 mi...

With so many shares to choose from on the Australian share market, it can be difficult to decide which ones to buy. The good news is that brokers across the country are doing a lot of the hard work for you. Three top ASX shares that leading...

Many ASX sectors, such as ASX gold shares, tech shares and retail shares, have delivered strong returns over the past year or so. As such, many investors may be wondering where to look for buying opportunities. Well, some analysts have i...